参考文献
［1］CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015［J］. CA: a cancer journal for clinicians, 2016, 66（2）: 115-132.
［2］TORRE L A, BRAY F, SIEGEL R L, et al. Global cancer statistics, 2012［J］. CA: a cancer journal for clinicians, 2015, 65（2）: 87-108.
［3］ABNET C C, ARNOLD M, WEI W Q. Epidemiology of esophageal squamous cell carcinoma［J］. Gastroenterology, 2018, 154（2）: 360-373.
［4］ENZINGER P C, MAYER R J. Esophageal cancer［J］. The New England Journal of Medicine, 2003, 349（23）: 2241-2252.
［5］KORST R J, ALTORKI N K. Imaging for esophageal tumors［J］. Thoracic Surgery Clinics, 2004, 14（1）: 61-69.
［6］AMIN M B, EDGE S B, GREENE F L. AJCC cancer staging manual［M］. 8th ed. New York, NY: Springer, 2017.
［7］AJANI J A, D’AMICO T A, ALMHANNA K, et al. Esophageal and esophagogastric junction cancers, version 1. 2015［J］. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13（2）: 194-227.
［8］VAN HAGEN P, HULSHOF M C, VAN LANSCHOT J J, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer［J］. The New England Journal of Medicine, 2012, 366（22）: 2074-2084.
［9］ARNOTT S J, DUNCAN W, GIGNOUX M, et al. Preoperative radiotherapy in esophageal carcinoma: a meta-analysis using individual patient data（oesophageal cancer collaborative group）［J］. International Journal of Radiation Oncology, Biology, Physics, 1998, 41（3）: 579-583.
［10］KIDANE B, COUGHLIN S, VOGT K, et al. Preoperative chemotherapy for resectable thoracic esophageal cancer［J］. The Cochrane Database of Systematic Reviews, 2015, 2015（5）: Cd001556.
［11］MARIETTE C, DAHAN L, MORNEX F, et al. Surgery alone versus chemoradiotherapy followed by surgery for stage Ⅰ andⅡ esophageal cancer: final analysis of randomized controlled phase Ⅲ trial FFCD 9901［J］. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2014, 32（23）: 2416-2422.
［12］YANG H, LIU H, CHEN Y, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus（neocrtec5010）: a phase Ⅲ multicenter, randomized, open-label clinical trial［J］. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2018, 36（27）: 2796-2803.
［13］ZHANG X, SHEN L, LI J, et al. A phase Ⅱ trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus［J］. American Journal of Clinical Oncology, 2008, 31（1）: 29-33.
［14］ILSON D H, FORASTIERE A, ARQUETTE M, et al. A phaseⅡ trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus［J］. Cancer Journal（Sudbury, Mass）, 2000, 6（5）: 316-323.
［15］LORENZEN S, SCHUSTER T, PORSCHEN R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase Ⅱ study of the Arbeitsgemeinschaft Internistische Onkologie［J］. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 2009, 20（10）: 1667-1673.
［16］TEPPER J, KRASNA M J, NIEDZWIECKI D, et al. PhaseⅢ trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781［J］. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2008, 26（7）: 1086-1092.
［17］CHEN Y, YE J, ZHU Z, et al. Comparing paclitaxel plus fluorouracil versus cisplatin plus fluorouracil in chemoradiotherapy for locally advanced esophageal squamous cell cancer: a randomized, multicenter, phase Ⅲ clinical trial［J］. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2019, 37（20）: 1695-1703.
［18］ILSON D H, WADLEIGH R G, LEICHMAN L P, et al. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer［J］. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 2007, 18（5）: 898-902.
［19］ALBERTSSON M, JOHANSSON B, FRIESLAND S, et al. Phase Ⅱ studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer［J］. Medical Oncology（Northwood, London, England）, 2007, 24（4）: 407-412.
［20］JIN J, XU X, WANG F, et al. Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatinpretreated refractory metastatic/recurrent esophageal squamous cell carcinoma［J］. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer, 2009, 4（8）: 1017-1021.
［21］KIM J Y, DO Y R, PARK K U, et al. A multi-center phase Ⅱstudy of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer［J］. Cancer Chemotherapy and Pharmacology, 2010, 66（1）: 31-36.
［22］LEE S J, KIM S, KIM M, et al. Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase Ⅱ study［J］. BMC Cancer, 2015, 15: 693.
［23］GIORDANO K F, JATOI A, STELLA P J, et al. Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase Ⅱ study from the North Central Cancer Treatment Group［J］. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 2006, 17（4）: 652-656.
［24］OSAKA Y, SHINOHARA M, HOSHINO S, et al. Phase Ⅱstudy of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer［J］. Anticancer Research, 2011, 31（2）: 633-638.
［25］SHAH M A, JANJIGIAN Y Y, STOLLER R, et al. Randomized multicenter phase Ⅱ study of modified docetaxel, cisplatin, and fluorouracil（DCF）versus dcf plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the us gastric cancer consortium［J］. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2015, 33（33）: 3874-3879.
［26］ILSON D H. Phase Ⅱ trial of weekly irinotecan/cisplatin in advanced esophageal cancer［J］. Oncology（Williston Park, NY）, 2004, 18（14 Suppl 14）: 22-25.
［27］BANG Y J, VAN CUTSEM E, FEYEREISLOVA A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer（ToGA）: a phase 3, open-label, randomised controlled trial［J］. Lancet（London, England）, 2010, 376（9742）: 687-697.
［28］LI J, QIN S, XU J, et al. Randomized, double-blind, placebo-controlled phase Ⅲ trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction［J］. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2016, 34（13）: 1448-1454.
［29］FUCHS C S, TOMASEK J, YONG C J, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma（REGARD）: an international, randomised, multicentre, placebo-controlled, phase 3 trial［J］. Lancet（London, England）, 2014, 383（9911）: 31-39.
［30］WILKE H, MURO K, VAN CUTSEM E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma（RAINBOW）: a double-blind, randomised phase 3 trial［J］. The Lancet Oncology, 2014, 15（11）: 1224-1235.
［31］DE CASTRO JUNIOR G, SEGALLA J G, DE AZEVEDO S J, et al. A randomised phase Ⅱ study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial［J］. European Journal of Cancer（Oxford, England: 1990）, 2018, 88: 21-30.
［32］DUTTON S J, FERRY D R, BLAZEBY J M, et al. Gefitinib for oesophageal cancer progressing after chemotherapy（COG）: a phase 3, multicentre, double-blind, placebo-controlled randomised trial［J］. The Lancet Oncology, 2014, 15（8）: 894-904.
［33］HUANG J, FAN Q, LU P, et al. Icotinib in patients with pretreated advanced esophageal squamous cell carcinoma with EGFR overexpression or EGFR gene amplification: a single-arm, multicenter phase 2 study［J］. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer, 2016, 11（6）: 910-917.
［34］ZHAO C, LIN L, LIU J, et al. A phase Ⅱ study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma［J］. Oncotarget, 2016, 7（35）: 57310-57316.
［35］WU S X, WANG L H, LUO H L, et al. Randomised phaseⅢ trial of concurrent chemoradiotherapy with extended nodal irradiation and erlotinib in patients with inoperable oesophageal squamous cell cancer［J］. European Journal of Cancer（Oxford, England: 1990）, 2018, 93: 99-107.
［36］MURO K, CHUNG H C, SHANKARAN V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer（KEYNOTE-012）: a multicentre, open-label, phase 1b trial［J］. The Lancet Oncology, 2016, 17（6）: 717-726.
［37］FUCHS C S, DOI T, JANG R W, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial［J］. JAMA Oncology, 2018, 4（5）: e180013.
［38］JOSEP T, YUNG-JUE B, CHARLES S F, et al. KEYNOTE-062: phase Ⅲ study of pembrolizumab（MK-3475）alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction（GEJ）adenocarcinoma［J］. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2019, 34（4_suppl）: LBA4007.
［39］KOJIMA T, MURO K, FRANCOIS E, et al. Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: phase Ⅲ KEYNOTE-181 study［J］. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2019, 37（4_suppl）: 2.
［40］JANJIGIAN Y Y, BENDELL J, CALVO E, et al. CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer［J］. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2018, 36（28）: 2836-2844.
［41］DOI T, PIHA-PAUL S A, JALAL S I, et al. Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma［J］. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2018, 36（1）: 61-67.
［42］SHAH M A, KOJIMA T, HOCHHAUSER D, et al. Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study［J］. JAMA Oncology, 2019, 5（4）: 546-550.
［43］KUDO T, HAMAMOTO Y, KATO K, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an openlabel, multicentre, phase 2 trial［J］. The Lancet Oncology, 2017, 18（5）: 631-639.
［44］BEDENNE L, MICHEL P, BOUCHÉ O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102［J］. J Clin Oncol. 2007, 25（10）: 1160-1168.
［45］ROBB WB, MESSAGER M, DAHAN L, et al. Patterns of recurrence in early-stage oesophageal cancer after chemoradiotherapy and surgery compared with surgery alone［J］. Br J Surg. 2016, 103（1）: 117-125.